Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target.
The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
